Quick Facts

• Primary Use: Treatment of symptoms associated with seasonal allergic rhinitis.
• Symptom Relief: May assist in managing sneezing, runny nose (rhinorrhea), and nasal itching.

Ticalast (azelastine hydrochloride and fluticasone propionate) is an approved prescription medication used to address symptoms associated with seasonal allergic rhinitis, commonly known as hay fever. This medication may offer relief for a range of nasal symptoms.

Its therapeutic objective is to help manage uncomfortable and disruptive signs of seasonal allergies, including sneezing, an excess of a runny nose (rhinorrhea), and the sensation of nasal itching. By helping to reduce these symptoms, the medication supports patients in achieving a greater degree of comfort and stability in their daily activities during allergy season.

The medication is utilized as an option to help control and stabilize the chronic symptoms of seasonal allergic rhinitis in adult and pediatric patients who meet the criteria for treatment. It is not intended for the relief of acute or sudden breathing problems and should be administered only as directed by a qualified healthcare professional.

Eligibility Map: Who can and cannot use Ticalast

Eligibility Scope

Condition-Based Restrictions

Official labeling defines specific conditions where use is restricted or conditional:

• Comorbidities: Use requires caution and close monitoring for patients with a history of glaucoma or cataracts, untreated systemic infections (e.g., tuberculosis, ocular herpes simplex), or severe hepatic impairment.
• Wound Healing: Use must be avoided in patients with recent nasal surgery, trauma, or ulcers until healing is complete.
• Physiological States: During pregnancy or lactation, use is permitted only if the regulatory-defined potential benefit justifies the potential risk to the fetus or infant.

Age-Specific Consideration

Pediatric patients receiving the medicine require routine growth monitoring due to the potential risk associated with intranasal corticosteroids. No dosage adjustment is generally required for older adult patients.

Interactions with other medicines and products

This section describes formally documented interaction patterns strictly based on authoritative regulatory information for the azelastine hydrochloride and fluticasone propionate combination.

Pharmacokinetic and Pharmacodynamic Interactions

Metabolic Pathway Inhibition: The fluticasone propionate component is metabolized extensively by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with potent CYP3A4 inhibitors results in a pharmacokinetic interaction that significantly reduces the clearance of fluticasone, leading to increased systemic exposure. This increased exposure raises the risk of systemic corticosteroid effects.

CNS Additive Effects: Azelastine hydrochloride is an H₁-receptor antagonist with a known potential for sedation. Co-use with other Central Nervous System (CNS) depressants or alcohol creates a pharmacodynamic interaction, leading to an additive effect that further impairs alertness and CNS performance. Regulatory documentation specifies that co-administration with these substances should be avoided.

Documented Restrictions and Precautions

Population-Specific Caution: Caution is explicitly warranted for patients with severe hepatic impairment, as reduced clearance through first-pass metabolism is likely to increase the systemic exposure of the fluticasone propionate component.

Ticalast is a fixed-dose combination containing azelastine and fluticasone propionate, which exert distinct but complementary pharmacodynamic actions predominantly within the nasal mucosa.

Azelastine functions primarily as a selective Histamine H1-receptor antagonist. It occupies and blocks the H1-receptor, preventing the binding and activity of endogenous histamine. This H1-receptor antagonism modulates the downstream cellular responses typically mediated by histamine. Additionally, azelastine exhibits mast cell-stabilizing properties, inhibiting the release of pro-inflammatory mediators, including histamine, leukotrienes, and cytokines (e.g., TNF-alpha and IL-6), from the mast cells.

Fluticasone propionate acts as a glucocorticoid receptor agonist. Following intracellular binding, the drug-receptor complex translocates to the nucleus, where it modifies gene transcription. This genomic action results in the suppression of multiple inflammatory cells, including eosinophils, mast cells, and T-lymphocytes, and the down-regulation of pro-inflammatory mediators such as cytokines, eicosanoids, and adhesion molecules. The combined actions modify the cascade of cellular and molecular events that modulate local vascular permeability, mucus production, and cellular infiltration, resulting in systemic modulation of local physiological responses.

Official Administration Guidelines for Ticalast

Ticalast, a combination intranasal spray, must be administered strictly according to the prescribed instructions for correct dosing and procedural technique. The medication is for intranasal use only and must not be swallowed or sprayed into the eyes.

Dosing and Frequency

• Recommended Dose: Administer one spray into each nostril.
• Frequency: Use the spray twice daily (e.g., in the morning and evening).
• Missed Dose: If a dose is missed, use it as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not administer two doses at once.

Preparation and Procedure

The final administration of Ticalast must adhere to this precise, twice-daily schedule and technique to ensure the proper amount of medication is delivered to the nasal passages.

Research Evidence and Overview of Studies for Ticalast (Azelastine/Fluticasone Propionate)

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

The research base for Ticalast's use in seasonal allergic rhinitis, commonly known as hay fever, includes multiple short-term randomized controlled trials (RCTs). These studies were structured to compare the combination spray against a placebo (an inactive spray) and against the individual active ingredients, azelastine or fluticasone. Most of these trials focused on adults and adolescents (12 years and older) who reported moderate to severe seasonal nasal symptoms. This research examined symptom measurements over a short duration.

Researchers focused on tracking the Total Nasal Symptom Score (TNSS), a score that combines measurements of nasal congestion, runny nose, nasal itching, and sneezing. These studies explored symptom measurements over a defined time interval, often two weeks, and also monitored reported changes over time. The findings describe patterns observed in the measured symptom scores over the short treatment durations, with researchers reporting the comparative data collected in the combination group, the monotherapy groups, and the placebo group.

Evidence for Use in Persistent Allergic Rhinitis (PAR)

Evidence for the combination's use in patients experiencing chronic, year-round, or persistent allergic rhinitis also includes randomized controlled trials. These studies examined the experience of adults with chronic symptoms, where symptoms may be unstable throughout the year. The research explored symptom intensity and variability over intermediate durations, such as six to twelve weeks, to observe measurements over an extended time frame.

What is Still Uncertain About the Evidence Base

While Ticalast was studied for both seasonal and persistent allergic rhinitis, several areas of uncertainty remain in the research landscape. Key limitations include limited information for long-term outcomes regarding sustained observation beyond three months. Also, the research results apply most strongly to the populations studied (moderate to severe symptoms). Data for certain special groups, such as older adults, remain somewhat insufficient, and research is less extensive for the youngest children (ages 6 to 11) compared to the data collected for the adult/adolescent group.

Key Studies & References Azelastine hydrochloride nasal spray and its combination with fluticasone propionate in the management of allergic rhinitis

How to Store and Dispose of Ticalast?

The storage and disposal of this medicine must strictly follow regulatory instructions to maintain product stability and ensure safety.

Official Storage Conditions

Ticalast (azelastine and fluticasone propionate nasal spray) must be stored at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the product from freezing and not to refrigerate it. The bottle must be kept in its original container with the cap tightly closed and stored out of the sight and reach of children.

Stability and Disposal

This medicine should be discarded after 120 sprays have been used or 6 months after first opening the bottle, whichever occurs first. Unused or expired medication must be disposed of properly, preferably through a drug take-back program. Medicines should not be flushed down a toilet or poured into a drain unless specifically instructed by regulatory guidance.